Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.92 - $6.58 $20,148 - $45,402
-6,900 Reduced 7.62%
83,700 $257,000
Q1 2024

May 15, 2024

BUY
$3.41 - $5.74 $283,712 - $477,568
83,200 Added 1124.32%
90,600 $514,000
Q4 2023

Feb 14, 2024

SELL
$1.15 - $4.79 $8,049 - $33,530
-7,000 Reduced 48.61%
7,400 $31,000
Q3 2023

Nov 14, 2023

SELL
$1.28 - $2.41 $19,072 - $35,909
-14,900 Reduced 50.85%
14,400 $19,000
Q2 2023

Aug 14, 2023

SELL
$1.17 - $2.03 $24,687 - $42,832
-21,100 Reduced 41.87%
29,300 $44,000
Q1 2023

May 15, 2023

BUY
$1.58 - $3.41 $41,080 - $88,660
26,000 Added 106.56%
50,400 $88,000
Q4 2022

Feb 14, 2023

SELL
$2.0 - $3.58 $65,200 - $116,708
-32,600 Reduced 57.19%
24,400 $51,000
Q3 2022

Nov 14, 2022

BUY
$2.95 - $4.83 $52,805 - $86,457
17,900 Added 45.78%
57,000 $178,000

Others Institutions Holding ABSI

About Absci Corp


  • Ticker ABSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 92,843,504
  • Market Cap $383M
  • Description
  • Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process....
More about ABSI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.